CMPXEarnings•globenewswire•
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
Sentiment:Negative (30)
Summary
BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire